Definitions

from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. A meglitinide drug for the treatment of type II diabetes that lowers blood glucose by stimulating the release of insulin from the pancreas.

Etymologies

Sorry, no etymologies found.

Examples

  • Effect of nateglinide on the incidence of diabetes and cardiovascular events.

    Mark Hyman, MD: Millions Die Due to Withheld Medical Treatment

  • In fact, three of the newer medicines — acarbose and miglitol (both alpha-glucosidase inhibitors) and nateglinide (a meglitinide) — actually decrease HbA1c less than some of the older drugs.

    Diabetes Alert Day: 8 ways to live longer

  • In fact, three of the newer medicines—acarbose and miglitol (both alpha-glucosidase inhibitors) and nateglinide (a meglitinide)—actually decrease HbA1c less than some of the older drugs.

    Diabetes Alert Day: 8 ways to live longer

  • Group randomly assigned over 9000 individuals with impaired glucose tolerance who also had cardiovascular disease or risk factors for cardiovascular disease to take the drug nateglinide or a placebo up to three times a day.

    WN.com - Articles related to Hypertension study reveals benefits of online tracking

  • Conclusions Among persons with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors, assignment to nateglinide for 5 years did not reduce the incidence of diabetes or the coprimary composite cardiovascular outcomes.

    New England Journal of Medicine

  • We evaluated the effect of nateglinide on the occurrence of three coprimary outcomes: the development of diabetes; a core cardiovascular outcome that was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure; and an extended cardiovascular outcome that was

    New England Journal of Medicine

  • The study assessed whether valsartan or the oral anti-diabetic agent nateglinide could delay progression to diabetes or reduce the incidence of cardiovascular events in people with IGT and cardiovascular disease or risk factors.

    Top Headlines - Diabetes Health

  • Neither valsartan nor nateglinide is currently indicated for the treatment of patients with IGT.

    Top Headlines - Diabetes Health

  • In addition to background therapy and a study-specific lifestyle modification program, patients were randomized to receive either valsartan, nateglinide, valsartan and nateglinide together, or placebo.

    Top Headlines - Diabetes Health

  • Valsartan therapy did not show a reduction in the risk of cardiovascular events in this well-managed group of patients, while nateglinide-based therapy did not show a reduction in the incidence of new-onset diabetes or of cardiovascular events in this study population.

    Top Headlines - Diabetes Health

Comments

Log in or sign up to get involved in the conversation. It's quick and easy.